Exclusive-Nationalised German energy firms pay traders big bonuses after losing billions

By Dmitry Zhdannikov, Marwa Rashad and Christoph Steitz LONDON/FRANKFURT (Reuters) – German energy firms Sefe and Uniper have awarded some traders millions of dollars in bonuses for 2022, four sources familiar with the matter said, just months after the companies were rescued with multi-billion bailouts as Russia halted gas supplies. Germany has so far provided…

Read More

Exclusive-Kioxia, Western Digital speed up merger talks as memory chip demand slumps -sources

By Maki Shiraki and Makiko Yamazaki TOKYO (Reuters) – Kioxia Holdings Corp and Western Digital Corp are speeding up merger talks and nailing down a deal structure, two sources with direct knowledge of the matter said, as a slumping flash memory market puts fresh consolidation pressure on the world’s No. 2 and No. 4 players….

Read More

Australia’s InvoCare gets higher $1.3 billion offer from TPG, shares jump

By Scott Murdoch and Himanshi Akhand (Reuters) -Australia’s InvoCare Ltd shares jumped nearly 12% on Monday after it revealed a higher A$1.86 billion ($1.26 billion) offer from global private equity firm TPG had been tabled just weeks after it rejected a lower bid it said undervalued the funeral services provider. Shares of InvoCare rose to…

Read More

US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute

By Blake Brittain WASHINGTON (Reuters) – The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc’s challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva’s appeal of a lower court’s ruling reinstating the jury award…

Read More

Sarepta surges after FDA panel backs Duchenne gene therapy

By Aditya Samal (Reuters) -Shares of Sarepta Therapeutics jumped 25% on Monday as a backing by the U.S. health regulator’s advisers increased the certainty of an accelerated approval for the company’s gene therapy for a muscle-wasting genetic disorder. The stock was set for its biggest percentage jump in over three years, while the drugmaker’s market…

Read More